kaposi
sarcomaassoci
herpesviru
kshv
associ
kaposi
sarcoma
primari
effus
lymphoma
pel
kshv
replic
transcript
activ
rta
latencyassoci
nuclear
antigen
lana
play
key
role
activ
kshv
lytic
replic
maintain
kshv
latenc
respect
phosphorodiamid
morpholino
oligom
pmo
similar
short
singlestrand
dna
oligom
possess
modifi
backbon
confer
highli
specif
bind
resist
nucleas
studi
rta
lana
mrna
pel
cell
target
antisens
peptideconjug
pmo
ppmo
effort
suppress
kshv
replic
highli
effici
ppmo
uptak
pel
cell
observ
treatment
pel
cell
rta
ppmo
reduc
rta
express
dosedepend
sequencespecif
manner
also
caus
signific
decreas
sever
kshv
earli
late
gene
product
includ
kshv
viral
dna
level
reduc
cell
cultur
supernat
ppmotreat
cell
indic
kshv
lytic
replic
suppress
treatment
cell
ppmo
lana
result
reduct
lana
express
cell
viabil
assay
detect
cytotox
ppmo
alon
within
concentr
rang
use
experi
studi
result
suggest
ppmo
specif
block
kshv
replic
studi
warrant
nucleic
acidbas
strategi
use
block
gene
express
includ
rna
decoy
antisens
compound
rna
decoy
oligoribonucleotid
compet
translat
activ
mrnastabil
element
caus
translat
inhibit
mrna
destruct
beelman
parker
liebhab
antisens
strategi
employ
variou
structur
type
rnaor
dnabas
oligom
ribozym
dnazym
smallinterf
rna
sirna
approach
base
watsoncrick
basepair
antisens
agent
complementari
sequenc
mrna
select
target
use
vivo
strategi
like
need
util
modifi
nucleic
acid
backbon
structur
provid
protect
host
nucleas
addit
candid
therapeut
must
abl
effect
enter
cell
relev
tissu
access
target
rna
pmo
structur
similar
singlestrand
dna
oligonucleotid
differ
backbon
morpholin
ring
replac
deoxyribos
sugar
phosphorodiamid
linkag
replac
phosphodiest
linkag
dna
fig
schmajuk
et
al
summerton
pmo
uncharg
watersolubl
highli
resist
nucleas
degrad
hudziak
et
al
typic
synthes
approxim
base
length
pmo
bind
target
mrna
prevent
translat
initi
steric
blockad
distinct
rnase
hdepend
mechan
action
induc
antisens
structur
type
base
dna
chemistri
summerton
addit
pmo
conjug
russo
et
al
size
latent
transcript
indic
line
predict
splice
event
ie
sun
et
al
latent
transcript
dittmer
et
al
talbot
et
al
schemat
illustr
small
posit
charg
peptid
far
greater
deliveri
effici
cell
cultur
nonconjug
pmo
moulton
et
al
sequencespecif
antivir
efficaci
pmo
compound
cell
cultur
document
calicivirus
stein
et
al
hepat
c
viru
rna
mccaffrey
et
al
mous
hepat
viru
neuman
et
al
sar
coronaviru
neuman
et
al
equin
arter
viru
van
den
born
et
al
sever
flavivirus
dea
et
al
kinney
et
al
pmo
extens
use
studi
gene
function
zebrafish
development
embryolog
model
relev
studi
human
diseas
corey
abram
naseviciu
ekker
penberthi
et
al
scholpp
brand
knowledg
applic
pmotechnolog
dna
viru
yet
report
studi
morpholino
antisens
approach
util
reduc
product
replic
transcript
activ
rta
well
latencyassoci
nuclear
antigen
lana
protein
kaposi
sarcomaassoci
herpesviru
kshv
kshv
larg
dna
viru
associ
kaposi
sarcoma
ks
type
skin
tumor
recogn
common
malign
among
patient
aid
kshv
also
associ
sever
lymphoprolif
disord
includ
primari
effus
lymphoma
pel
multicentr
castleman
diseas
mcd
cesarman
et
al
chang
et
al
soulier
et
al
like
herpesvirus
kshv
caus
two
mode
infect
latent
lytic
latenc
kshv
genom
persist
limit
gene
express
host
cell
fakhari
dittmer
sarid
et
al
lana
encod
major
role
mainten
kshv
latenc
ballesta
et
al
lan
et
al
lim
et
al
lim
et
al
shinohara
et
al
lana
interact
repress
transcript
activ
friborg
et
al
target
transcript
regulatori
pathway
transform
primari
rat
cell
cooper
oncogen
hra
radkov
et
al
lana
also
upregul
telomeras
promot
modul
host
cellular
gene
express
renn
et
al
mutagen
disrupt
lead
abort
kshv
episom
persist
ye
et
al
kshv
latenc
disrupt
viru
switch
lytic
phase
infecti
virion
produc
spread
cell
cell
lytic
reactiv
viru
replic
pel
cell
induc
variou
chemic
phorbol
ester
tetradecanoyl
phorbol
acet
tpa
sodium
butyr
renn
et
al
kshv
lytic
replic
divid
immediateearli
earli
late
stage
key
immediateearli
gene
encod
rta
protein
activ
viral
lytic
gene
express
sun
et
al
rta
activ
downstream
viral
gene
earli
late
kinet
class
includ
mani
cellular
homologu
nonstructur
gene
homologu
macrophag
inflammatori
protein
ii
vcyclin
viral
gproteincoupl
receptor
gpcr
homologu
proinflammatori
cytokin
consid
essenti
develop
kshvassoci
malign
ensoli
et
al
moor
et
al
kshvinfect
pel
cell
ks
lesion
low
percentag
cell
maintain
kshv
lytic
replic
miller
et
al
lytic
cycl
activ
pivot
event
cascad
event
involv
kshv
replic
rta
essenti
control
factor
viral
replic
lytic
phase
contribut
develop
kshvassoci
diseas
report
demonstr
highli
effici
uptak
ppmo
kshvinfect
cell
well
highli
effect
sequencespecif
inhibit
rta
lana
protein
express
viral
gene
characterist
express
downstream
rta
also
suppress
result
specif
ppmomedi
inhibit
kshvinfect
cell
ebvposit
ebvneg
deriv
bodi
cavitybas
lymphoma
cesarman
et
al
renn
et
al
bjab
kshvand
ebvneg
lymphoma
cell
line
menez
et
al
cell
line
maintain
rpmi
medium
supplement
fetal
bovin
serum
cell
number
count
use
hemocytomet
cell
viabil
assess
trypan
blue
exclus
induct
kshv
lytic
replic
tpa
sigma
st
loui
mo
ad
cell
growth
medium
final
concentr
ngml
pmo
synthes
purifi
avi
biopharma
inc
corval
previous
describ
summerton
weller
design
complementari
specif
kshv
rna
sequenc
pmo
coval
conjug
end
peptid
nh
rrrrrffrrrrcconh
design
r
f
r
fig
method
conjug
purif
analysi
r
f
r
pmo
hereaft
refer
ppmo
similar
describ
previous
pmocompound
use
studi
target
site
kshv
summar
tabl
depict
fig
fluorescein
conjug
end
control
pmo
sequenc
nonconjug
pmofl
peptideconjug
ppmofl
form
see
tabl
assess
pmo
uptak
cell
complementari
oligonucleotid
sequenc
base
rel
aug
translat
initi
codon
synthes
clone
luciferas
report
vector
manner
similar
describ
previous
neuman
et
al
insert
leader
sequenc
includ
ppmo
target
region
clone
upstream
augabl
luciferas
sequenc
report
vector
dna
sequenc
conduct
confirm
insert
sequenc
infram
luciferas
open
read
frame
plasmid
dna
linear
downstream
targetluciferas
fusion
gene
vitro
transcript
conduct
megascript
kit
ambion
austin
tx
cellfre
translat
reaction
perform
rabbit
reticulocyt
lysat
system
promega
madison
wi
differ
concentr
ppmo
ad
translat
reaction
order
determin
abil
inhibit
luciferas
product
sequenc
homolog
includ
assay
control
luciferas
activ
cellfre
translat
reaction
measur
use
micropl
luminomet
biotek
instrument
inc
winooski
vt
rel
light
unit
produc
reaction
normal
mean
control
reaction
express
percent
inhibit
luciferas
translat
cell
count
pellet
resuspend
rpmi
medium
supplement
gml
bovin
serum
albumin
bsa
cell
transfer
cell
cultur
plate
cell
per
well
immedi
pmo
compound
applic
cell
incub
c
gentl
shake
h
cell
pellet
wash
phosphatebuff
salin
pb
ph
remov
free
pmocompound
observ
fluoresc
microscop
flow
cytometri
analysi
pmoppmotr
cell
pellet
fix
paraformaldehyd
pb
min
room
temperatur
analyz
facscalibur
system
use
cellquest
softwar
program
version
bd
bioscienc
san
jose
ca
green
fluoresc
measur
use
nm
band
pass
filter
test
whether
ppmo
could
stabli
persist
cell
cell
cultur
growth
medium
rpmi
supplement
fetal
bovin
serum
treat
describ
harvest
h
analysi
fluoresc
microscopi
flow
cytometri
kshvinfect
cell
count
pellet
resuspend
rpmi
medium
supplement
gml
bsa
cell
transfer
cell
cultur
plate
cell
per
well
immedi
ppmo
treatment
ppmo
dilut
cultur
media
ad
cell
control
ppmo
includ
neg
control
cell
treat
pb
includ
mocktreat
control
mix
cell
incub
h
c
growth
medium
supplement
tpa
ngml
ad
final
volum
ml
per
well
cell
incub
h
c
cell
cultur
supernat
harvest
analysi
timekinet
analysi
tpa
ad
cell
h
commenc
ppmo
treatment
growth
medium
ad
cell
h
ppmo
treatment
lana
ppmo
treatment
protocol
follow
tpa
omit
growth
medium
recurr
applic
lana
ppmo
interv
cell
also
test
describ
ifa
util
detect
protein
cell
describ
previous
gao
et
al
briefli
cell
pellet
rins
pb
three
time
spot
onto
slide
slide
heatfix
h
c
polyclon
rabbit
antirta
antibodi
use
detect
rta
express
wang
et
al
mous
monoclon
antibodi
gift
dr
keiji
ueda
osaka
univers
school
medicin
japan
mous
monoclon
antibodi
glycoprotein
encod
kshv
rat
antilana
monoclon
antibodi
polyclon
rabbit
antibodi
advanc
biotechnolog
inc
columbia
md
use
detect
lana
protein
cell
respect
goat
antimous
iggfluorescein
isothiocyn
fitc
antirat
iggfitc
antirabbit
iggfitc
sigma
conjug
use
identifi
specif
reaction
stain
cell
observ
fluoresc
microscopi
flow
cytometri
analysi
cell
fix
paraformaldehyd
permeabil
triton
pb
min
room
temperatur
rabbit
antirta
antibodi
goat
antirabbit
iggfitc
conjug
use
detect
rta
protein
stain
cell
resuspend
pb
analyz
facscalibur
system
bd
bioscienc
describ
cell
mockstain
stain
secondari
antibodi
includ
neg
control
rta
protein
express
kshvinfect
cell
identifi
western
blot
analysi
cell
lyse
resolv
polyacrylamid
gel
sdspage
separ
protein
transfer
nitrocellulos
membran
probe
rabbit
antirta
antiserum
specif
reaction
detect
goat
antirabbit
igg
conjug
horseradish
peroxidas
sigma
addit
chemiluminesc
substrat
chemiluminisc
signal
collect
versadoc
digit
imag
system
biorad
laboratori
hercul
ca
tubulin
detect
blot
membran
normal
protein
load
analysi
similarli
protein
express
lana
gene
product
detect
respect
antibodi
describ
digit
imag
analys
conduct
use
quantiti
one
softwar
version
biorad
effect
ppmo
treatment
cell
viabil
determin
celltiterblu
promega
briefli
cell
treat
ident
condit
describ
section
absenc
viru
mocktreat
cell
includ
comparison
cell
without
tpa
induct
also
includ
control
celltiterblu
reagent
ad
incub
h
c
fluoresc
signal
measur
synergi
ht
multidetect
micropl
reader
biotek
singl
factor
anova
statist
analysi
conduct
test
target
protein
express
differ
group
pmotreat
cell
strum
kirk
twotail
pvalu
less
consid
signific
genom
dna
cell
cultur
supernat
isol
use
dnazol
invitrogen
carlsbad
ca
dna
cell
isol
wizard
genom
dna
purif
kit
promega
realtim
pcr
conduct
chromo
detector
system
biorad
use
primer
set
tgact
tcgcc
aaccg
tag
cctat
ggaga
tggga
gatgt
ag
expect
amplifi
sequenc
gene
iq
sybr
green
supermix
biorad
recombin
plasmid
rainbow
et
al
quantifi
use
gener
standard
curv
realtim
pcr
cellular
dna
also
amplifi
order
assur
normal
quantit
pcr
detect
kshv
dna
cell
ppmo
design
base
pair
immedi
earli
transcript
translat
initi
codon
region
fig
control
ppmo
fivebas
chang
sequenc
also
synthes
see
tabl
help
evalu
inhibit
rta
express
inde
sequencespecif
three
ppmo
design
target
complementari
lana
translat
initi
region
fig
ppmo
design
separ
sequenc
untransl
region
utr
latent
lana
transcript
fig
target
splice
donor
site
dittmer
et
al
talbot
et
al
pmo
neutral
charg
conjug
argininerich
peptid
assist
deliveri
varieti
cell
moulton
et
al
howev
literatur
concern
uptak
pmo
compound
b
lymphocyt
order
investig
issu
cell
incub
pmofl
final
concentr
media
h
incub
microscopi
reveal
virtual
cell
treat
exhibit
green
fluoresc
fig
fluoresc
observ
cell
treat
result
indic
highli
effici
uptak
poor
uptak
pmofl
cell
cultur
condit
flow
cytometri
analysi
conduct
quantifi
degre
cellular
uptak
high
percentag
cell
treat
h
fluorescenceposit
fig
cell
treat
fluorescenceneg
evalu
persist
uptak
cell
treat
h
rins
replenish
media
harvest
h
later
analysi
fluoresc
microscopi
flow
cytometri
green
fluoresc
still
observ
almost
cell
three
time
point
flow
cytometri
analysi
likewis
show
cell
green
fluoresc
three
time
point
fig
cell
treat
pb
includ
mocktreat
control
fluoresc
observ
cell
time
point
green
fluoresc
treat
cell
still
observ
day
treatment
show
reduc
intens
data
shown
reduct
fluoresc
intens
may
due
cell
divis
andor
signal
quench
character
ppmo
mediat
inhibit
translat
carri
use
rabbit
reticulocyt
lysat
cellfre
translat
assay
system
bind
ppmo
target
vitro
transcrib
rna
expect
reduc
translat
downstream
luciferas
report
luciferas
activ
reduc
treatment
doserespons
manner
inhibit
nm
comparison
mocktreat
control
ident
treatment
effect
indic
sequencespecif
mechan
caus
mediat
inhibit
fig
investig
abil
ppmo
interfer
translat
live
cell
appli
concentr
cell
determin
effect
rta
protein
express
untreat
noninduc
cell
less
cell
rtaposit
indic
small
number
cell
spontan
kshv
lytic
replic
expect
untreat
cell
tpa
induct
approxim
cell
express
rta
detect
ifa
fig
induc
cell
treatment
result
reduct
cell
signal
posit
rta
approxim
fig
cellfre
luciferas
report
assay
ppmo
ad
vitro
translat
reaction
contain
rna
transcrib
report
construct
includ
ppmo
target
sequenc
upstream
infram
firefli
luciferas
code
sequenc
ppmo
includ
neg
control
luciferas
activ
presenc
ppmo
compar
graph
percentag
mocktreat
reaction
set
averag
three
test
shown
error
bar
repres
variat
among
experi
compar
approxim
mocktreat
control
ppmo
cell
fig
inhibitori
effect
rta
express
examin
kshvinfect
cell
coinfect
ebv
cell
treat
manner
describ
cell
ifa
result
found
tpainduc
cell
treatment
markedli
reduc
number
rtaposit
cell
compar
mocktreat
cell
effect
data
shown
effort
confirm
ifa
observ
inhibit
western
blot
analysi
perform
determin
rta
protein
level
cell
tpa
induct
ppmo
treatment
cell
treat
seri
twofold
dilut
rang
cell
treat
pb
includ
mock
treatment
control
totalcel
lysat
subject
sdspage
western
blot
analysi
blot
show
level
rta
protein
express
tpainduc
cell
reduc
doserespons
manner
ppmo
fig
ident
treatment
ppmo
result
detect
chang
rta
express
fig
confirm
ifa
observ
quantit
digit
imag
analysi
reveal
treatment
tpainduc
cell
inhibit
rta
express
compar
mocktreat
fig
result
demonstr
inhibit
rta
protein
express
cell
dosedepend
sequencespecif
manner
flow
cytometri
also
conduct
result
confirm
ifa
western
blot
data
cell
treat
concentr
rta
detect
rabbit
antirta
antibodi
similar
ifa
analysi
less
noninduc
approxim
tpainduc
cell
rtaposit
approxim
induc
cell
treat
rtaposit
number
significantli
lower
mocktreat
cell
p
fig
cell
treat
profil
mock
treatment
control
shown
transcript
induc
within
h
addit
tpa
kshv
earli
lytic
gene
transcript
detect
h
tpa
induct
result
show
ppmo
inhibit
rta
protein
express
tpa
ad
h
post
ppmo
applic
character
kinet
activ
tpa
ad
cell
h
ppmo
applic
ifa
analysi
show
treatment
reduc
rta
protein
express
time
point
data
shown
ppmo
five
basechang
sequenc
test
ident
condit
effect
rta
protein
express
fig
confirm
sequencespecif
activ
rta
immediateearli
gene
play
key
role
activ
kshv
lytic
replic
inhibit
rta
protein
express
may
expect
block
kshv
lytic
replic
investig
possibl
express
kshv
lytic
gene
glycoprotein
encod
analyz
cell
western
blot
analysi
comparison
mocktreat
cell
tpa
induct
express
lytic
gene
decreas
dosedepend
manner
treatment
fig
fig
western
blot
analysi
evalu
inhibit
express
kshv
lytic
gene
downstream
cell
express
glycoprotein
encod
tpainduc
cell
reduc
increas
ppmo
concentr
ppmo
caus
detect
chang
b
quantit
imag
analysi
confirm
doserespons
inhibit
c
cell
treat
ppmo
comparison
mocktreat
cell
fig
fig
contrast
level
protein
cell
treat
detect
chang
fig
result
indic
inhibit
rta
express
result
reduct
kshv
lytic
replic
lana
latent
gene
product
express
constitut
kshvinfect
cell
determin
effect
treatment
kshv
latenc
western
blot
analysi
conduct
detect
lana
level
cell
treat
detect
chang
signal
gener
lana
antibodi
found
cell
comparison
mocktreat
cell
data
shown
also
assess
kshv
replic
pel
cell
post
treatment
realtim
pcr
conduct
intracellular
cell
cultur
supernat
sampl
order
measur
viral
dna
level
establish
addit
tpa
cell
cultur
media
lead
induct
kshv
lytic
replic
renn
et
al
experi
tpa
induct
increas
kshv
viral
dna
level
cell
cultur
supernat
respect
fig
cell
treat
viral
dna
level
similar
background
level
observ
mocktreat
sampl
kshv
viral
dna
level
post
treatment
high
post
treatment
result
demonstr
treatment
specif
result
inhibit
kshv
lytic
replic
cell
viabil
assay
conduct
ppmo
order
assess
cytotox
exclud
possibl
reduct
target
gene
express
test
cell
misinterpret
cell
treat
either
concentr
condit
ident
experi
cell
densiti
use
assay
within
linear
rang
method
detect
fluoresc
intens
cell
without
ppmo
treatment
includ
mock
treatment
control
rel
percentag
fluoresc
intens
calcul
comparison
mocktreat
control
assay
repeat
three
time
averag
percentag
cell
treat
cell
treat
noninduc
control
result
show
detect
cytotox
condit
use
experi
report
three
ppmo
design
target
lana
evalu
cell
applic
concentr
cell
effect
lana
express
accord
ifa
western
blot
analysi
lana
constitut
express
cell
high
level
recurr
applic
everi
day
total
day
test
chang
lana
level
detect
obtain
confirm
ppmo
capabl
bind
target
rna
cellfre
report
assay
rna
similar
system
describ
conduct
found
effect
inhibit
translat
report
system
data
shown
result
suggest
either
unabl
access
kshv
target
rna
cell
success
hybrid
target
rna
littl
biolog
impact
applic
concentr
cell
caus
reduct
lana
protein
level
detect
ifa
western
blot
fig
ifa
show
three
repeat
ppmo
treatment
cell
interv
reduc
lana
protein
express
recurr
applic
mock
treatment
detect
effect
fig
lana
protein
level
also
evalu
western
blot
analysi
lana
protein
express
significantli
reduc
threetim
treatment
fig
remain
stabl
mock
treatment
control
treat
gener
reduct
lana
protein
level
second
applic
reduct
third
applic
fig
appear
somewhat
potent
suppress
lana
protein
express
experi
studi
demonstr
ppmo
specif
suppress
protein
express
kshv
rta
lana
rta
fig
inhibit
lana
express
cell
immunofluoresc
assay
antilana
antibodi
show
inhibit
lana
protein
express
cell
cell
treat
three
time
day
interv
describ
text
cell
nuclei
counterstain
blue
dapi
mount
solut
molecular
probe
lower
imag
panel
taken
dapi
filter
field
upper
panel
note
lanastain
much
weaker
cell
treat
cell
treat
ppmo
mocktreat
total
lana
protein
express
also
evalu
western
blot
analysi
b
total
protein
three
treatment
collect
separ
use
western
blot
number
lane
repres
number
ppmo
applic
interv
cell
quantit
imag
analysi
confirm
lana
inhibit
second
third
applic
c
lana
protein
express
cell
treat
shown
percentag
rel
mocktreat
control
protein
requir
switch
process
latenc
lytic
replic
kshv
sun
et
al
rta
express
initi
viral
proinflammatori
cytokin
transform
gene
express
lytic
viral
replic
activ
sun
et
al
lana
crucial
maintain
kshv
latenc
thu
control
rta
lana
protein
express
may
effect
strategi
block
kshv
replic
kshvinfect
cell
difficult
effici
transfect
common
transfect
reagent
lukac
et
al
lukac
et
al
zhu
et
al
recent
report
describ
transfect
effici
cell
lipofectamin
liposom
invitrogen
approxim
zhu
et
al
pmo
noncharg
compound
therefor
use
cation
lipid
deliv
cultur
cell
ineffect
ghosh
iversen
morco
conjug
argininerich
peptid
pmo
proven
effici
mean
deliv
pmo
cultur
cell
studi
r
f
r
pmo
test
cellular
uptak
persist
cell
presenc
treat
cell
indic
r
f
r
assist
pmo
uptak
correspond
fail
uptak
assay
flow
cytometri
analysi
confirm
enter
cell
furthermor
persist
one
week
singl
applic
uptak
assay
conduct
absenc
serum
cell
cultur
media
r
f
r
pmo
use
studi
achiev
rel
poor
cellular
uptak
appli
presenc
serum
recent
report
howev
peptidepmo
conjug
rxr
xbpmo
capabl
effect
deliveri
cell
presenc
serum
dea
et
al
nelson
et
al
deliveri
relev
cell
vivo
major
challeng
develop
nucleic
acidbas
therapeut
strategi
test
efficaci
specif
ppmo
appli
kshvinfect
cell
cultur
test
effect
ppmo
target
protein
express
cell
distinct
relev
natur
kshv
infect
cell
line
deriv
patient
pel
ifa
western
blot
result
demonstr
ppmo
effect
block
rta
protein
express
cell
doserespons
sequencespecif
manner
control
ppmo
effect
remain
faint
rta
protein
express
cell
treat
suggest
cell
achiev
littl
uptak
ppmo
insuffici
quantiti
ppmo
made
way
subcellular
locat
rta
mrna
translat
specul
also
provid
potenti
explan
higher
ppmo
concentr
requir
cultur
cell
cellfre
report
assay
achiev
equival
degre
translat
inhibit
studi
show
ppmo
suppress
rta
protein
express
even
tpa
induct
conduct
time
ppmo
treatment
inhibit
rta
protein
express
less
effect
appli
tpa
induct
observ
consist
predict
mechan
ppmo
action
block
initi
rna
translat
protein
summerton
weller
cell
viabil
assay
indic
detect
cytotox
concentr
rang
use
studi
support
conclus
suppress
rta
lytic
gene
express
due
sequencespecif
natur
ppmo
inhibit
rta
mrna
translat
applic
high
concentr
ppmo
howev
may
advers
effect
cell
observ
applic
h
result
approxim
cell
mortal
inclus
bsa
reliev
advers
effect
ppmo
applic
cell
result
reduc
express
seri
viral
gene
gene
typic
express
tempor
downstream
rta
kshv
viral
dna
level
intracellular
cultur
supernat
sampl
also
reduc
result
demonstr
kshv
lytic
replic
abrog
cell
rta
ppmo
applic
pattern
rta
preemin
event
lytic
progress
consist
previou
public
curr
et
al
zhu
et
al
curr
et
al
show
methotrex
potent
antiinflammatori
agent
inhibitor
cellular
dihydrofol
reductas
reduc
express
prevent
express
lytic
gene
mechan
action
known
zhu
et
al
show
dnabas
extern
guidanc
sequenc
eg
target
rta
mrna
rnase
pbase
cleavag
found
effect
mean
suppress
kshv
lytic
replic
cell
despit
limit
transfect
effici
zhu
et
al
studi
strongli
suggest
rta
appropri
target
antivir
therapi
ppmo
target
utr
latent
transcript
encod
lana
effect
inhibit
lana
protein
product
indic
target
region
compound
essenti
translat
latent
transcript
efficaci
suggest
abl
inhibit
utr
splice
event
kb
latent
transcript
fig
lead
reduct
kb
transcript
encod
lana
latent
transcript
encod
splice
latent
transcript
lana
dittmer
et
al
talbot
et
al
ppmo
may
potenti
inhibit
translat
latent
transcript
well
design
lana
translat
startsit
region
detect
suppress
effect
lana
protein
express
specul
target
sequenc
region
latent
lana
transcript
may
inaccess
ppmo
cell
ppmo
effect
vitro
translat
report
assay
rna
secondari
structur
analysi
latent
transcript
use
mfold
program
zuker
reveal
complex
secondari
structur
like
exist
translat
initi
region
data
shown
current
antiherpesviru
drug
target
lytic
rather
latent
phase
report
cidofovir
foscarnet
effici
commerci
avail
compound
kshv
kede
ganem
medveczki
et
al
sergeri
boivin
cidofovir
foscarnet
effect
express
latent
earli
lytic
gene
curr
et
al
drug
inhibitor
viral
dna
polymeras
transcript
earli
lytic
gene
occur
dna
replic
kshv
lana
rta
earli
lytic
gene
jone
et
al
stasku
et
al
zimr
et
al
play
import
role
kshv
replic
pathogenesi
block
express
gene
therebi
downstream
gene
well
could
contribut
treatment
kshvassoci
malign
antisens
ppmo
compound
target
rta
lana
may
prove
effect
reagent
imped
kshv
replic
vivo
warrant
studi
